Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 1.00 |
| ▸ | PRKACG | P22612 | 4/20 | 1.00 |
| ▸ | PRKACB | P22694 | 4/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 11/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | GLI1 | P08151 | 1/20 | 0.38 |
| ▸ | GLI2 | P10070 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884246 | 0.83 | AHR (0.71) | SRCPRKACAPRKACGPRKACBAHR | |
| SCHEMBL12067594 | 0.80 | SRC (0.64) | SRCPRKACAPRKACGPRKACB | |
| SCHEMBL7987496 | 0.80 | SRC (1.00) | SRCPRKACAPRKACGPRKACBGPR35 | |
| SCHEMBL3876188 | 0.78 | SRC (0.64) | SRCPRKACAPRKACGPRKACBGPR35 | |
| SCHEMBL3876544 | 0.78 | SRC (0.64) | SRCPRKACAPRKACGPRKACBGPR35 | |
| SCHEMBL7980308 | 0.75 | SRC (1.00) | SRCPRKACAPRKACGPRKACBGPR35 | |
| SCHEMBL8140912 | 0.75 | SRC (0.58) | SRCPRKACAPRKACGPRKACBGPR35 | |
| SCHEMBL433122 | 0.75 | SRC (0.58) | SRCPRKACAPRKACGPRKACBGPR35 | |
| SCHEMBL29638855 | 0.75 | SRC (0.58) | SRCPRKACAPRKACGPRKACBGPR35 | |
| SCHEMBL7984052 | 0.73 | SRC (0.71) | SRCPRKACAPRKACGPRKACBGLI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080098535-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof | GLENN ROBERT W JR | 2008-05-01 | — | — | US | claimed |
| US-20050217038-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-10-06 | — | — | US | claimed |
| US-7491245-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080098535-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof | GLENN ROBERT W JR | 2008-05-01 | — | — | US | disclosed |
| US-7331997-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1735059-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005099656-A2 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050217038-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER & GAMBLE COMPANY, THE | 2005-10-06 | — | — | US | disclosed |
| US-6194439-B1 | ANTICANCER AGENT | PFIZER INC. | 2001-02-27 | — | — | US | disclosed |
| EP-0586608-A1 | TRICYCLIC POLYHYDROXYLIC TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992021660-A1 | TRICYCLIC POLYHYDROXYLIC TYROSINE KINASE INHIBITORS | PFIZER, INC. (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050217038-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, CKMT1A; CKMT1B, TUBB6 | SRC 2779/4885PRKACA 1460/4885PRKACG 1247/4885 |
| US-20080098535-A1 | Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof | KRT18, CKMT1A; CKMT1B, TUBB6 | SRC 2779/4885PRKACA 1460/4885PRKACG 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.